J&J/Ethicon Bets On Minimally Invasive CABG With $81 Mil. Heartport Buy
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's Ethicon subsidiary signaled its confidence in the future of minimally invasive coronary artery bypass grafting (CABG) with its Jan. 26 agreement to buy Heartport, Inc. for $81 mil.
You may also be interested in...
Guidant's CTS Buy Provides Platform For Growth In Cardiac Surgery Market
Guidant's planned acquisition of minimally invasive cardiac surgery device maker CardioThoracic Systems for $313 mil. in stock provides greater access to cardiac surgeons as well as a platform for growth in the cardiac surgery market.
Minimally Invasive Cardiac Surgery - Wave Of New Products Hits OR Market
Competing minimally invasive cardiac surgery (MICS) device manufacturers - CardioThoracic Systems, Medtronic and Heartport - have unveiled next-generation products in an effort to bolster acceptance among cardiac surgeons of MICS and overcome their fidelity to open chest procedures.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.